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S U M M A R Y
A 36-year-old African American female with a 14-year history of allergic fungal sinusitis (AFS) presented
with progressive worsening headache, fevers, proptosis, and a large frontal lobe brain mass. After
excisional biopsy, the non-invasive, dematiaceousmold, Bipolaris australiensis, was identiﬁed.We review
the epidemiology, etiology, pathophysiology, and clinical presentations of fungal sinusitis, as well as the
complex management and multifaceted therapeutic modalities of AFS.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Allergic fungal sinusitis (AFS) is most commonly caused by the
dematiaceous molds, Bipolaris, Curvularia and Pseudallescheria.
AFS is historically considered to be a non-invasive form of fungal
sinusitis, although it is well known to be associated with
signiﬁcant recurrence and morbidity, necessitating frequent
endoscopic and aggressive medical management. We report a
rare case of an invasive form of AFS to the central nervous system.
We review the epidemiology, etiology, pathophysiology, and
clinical presentations of fungal sinusitis. Additionally, in order
to decrease the elevatedmorbidity and recurrence rate, we discuss
the complexmanagement andmultifaceted therapeuticmodalities
of AFS.
2. The case
A 36-year-old African American female with a history of mild
intermittent childhood asthma and chronic allergic rhinosinusitis
presented with one-day severe headaches. Symptoms of allergic
rhinosinusitis began at age 22, for which she had undergone ﬁve
endoscopic nasal surgical procedures to removemultiple recurring
nasal polyps, at intervals of approximately 2 years. After each
procedure she developed nasal congestion, rhinorrhea, and facial
pain within a few months. At no time did she have fever or* Corresponding author. Tel.: +1 917 671 6299; fax: +1 713 798 8948.
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doi:10.1016/j.ijid.2010.02.2239systemic symptoms. Intermittently, she used twice daily sinus
irrigationwith warm isotonic saline via a bulb irrigator, along with
intranasal corticosteroids. Symptomswere almost continuous. She
had lived in New Orleans, Louisiana all her life and had moved to
Houston, Texas after Hurricane Katrina in late summer 2005.
In October 2004 she developed a subacute headache without
fever. Computed tomography revealed a large left frontal lobe
mass, which was resected and the cranium closed without any
organic or other material occupying the residual space. Cultures
revealed a mold. However, medical records from New Orleans
were unavailable, due to ﬂooding. She was discharged without any
complications after 3 weeks with instructions to take an unknown
oral antifungal medication for several more weeks as an
outpatient.
Symptoms ofmild allergic sinusitis recurred, and inMarch 2007
she began to have progressive worsening headache, subjective
fevers, and sinus pain. Seven months later she began to lose her
vision. She continued using intranasal corticosteroids, 10 mg oral
prednisone daily for 4 weeks, and isotonic saline irrigations to
remove nasal secretions. She was seen in the emergency
department in December 2007 with severe headache and left
proptosis.
On admission her vital signs werewithin normal limits. She had
total loss of visual perception bilaterally and a sluggish pupillary
reaction to light. Mild nasal edema but no necrotic tissue or mass
was visualized. Her strength, sensation, and gait were intact. A
complete blood count and differential were normal. Total serum
IgE was 183 IU/ml and HIV testing was negative. Computed
tomography of the head and facial bones revealed pansinusitisses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Computed tomography of the head with and without contrast: (A) frontal sinusitis with invasion to the frontal lobe and (B) extensive vasogenic edema resulting in
left-to-right subfalcial herniation.
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4.2  6.7 cm, extending from the left frontal sinus into the left
supraorbital frontal lobe (Figure 1). The mass was associated with
extensive vasogenic edema resulting in left-to-right subfalcial
herniation of approximately 6 mm.
She underwent emergent resection of the frontal lobemass and
ablation of the sinuses. Immediately, she was started on
amphotericin B deoxycholate, vancomycin, ceftriaxone, and
metronidazole. On subsequent days her symptoms greatly
improved with no neurological deﬁcits except for unchanged
bilateral visual loss and papilledema observed on fundoscopic
exam. Operative cultures grew a black mold on Sabouraud
dextrose agar plates, which was eventually identiﬁed as Bipolaris
australiensis (Figure 2). The diagnosis of allergic fungal sinusitis
complicated with central nervous system invasion was made.
Unfortunately, on the 14th day of admission, the patient had a
cardiac arrest and died, most likely from a massive saddle
pulmonary embolism.
3. Discussion
Recent studies suggest that fungi appear to play a major role in
the pathogenesis of chronic rhinosinusitis.1 Approximately 300Figure 2. Microscopic view of Bipolaris australiensis 100.fungal species are known to cause mycotic disease in humans and
other animals. More than 50 of these species are documented as
agents of rhinosinusitis. Most such infections are caused by species
of Aspergillus, Fusarium, Rhizopus, Alternaria, Bipolaris, Pseudal-
lescheria and Curvularia.2
The dematiaceous (brown-pigmented) fungi are a large and
heterogeneous group of molds that cause a wide range of diseases,
including phaeohyphomycosis, chromoblastomycosis, and eumy-
cotic mycetoma. These organisms are widespread in the environ-
ment, being found in soil, wood, and decomposing plant debris.
Disease occurs worldwide, but is more common in tropical and
subtropical climates.3 These dematiaceous fungi are unique, owing
to the presence of melanin in their cell walls, which imparts the
characteristic dark color to their spores and hyphae. Fontana–
Masson stains of tissue sections may be useful in conﬁrming the
diagnosis if culture results are negative.4
Interestingly, many of these cases have been encountered in
Texas, South Carolina, Arizona, and Georgia in the USA, Brisbane in
Australia, and in Pakistan and India.5 Schubert made similar
observations and reported Bipolaris spicifera to be the most
common cause of allergic fungal sinusitis in the southwestern
USA.6
It is crucial to recognize the different entities of fungal sinusitis,
which span the gamut from the most benign and non-invasive to
most malignant and invasive. These include AFS, sinus mycetoma,
granulomatous invasive fungal sinusitis, and chronic and acute
invasive fungal sinusitis.7 The invasive forms are usually caused by
hyaline molds (zygomycetes, Aspergillus and Fusarium), with few
caused by dematiaceous molds. Patients usually present with
fever, headache, epistaxis, cough, nasal mucosal ulcers or eschar,
and proptosis. In the majority of cases, patients are immunocom-
promised, with uncontrolled diabetes, hemochromatosis, or severe
malnutrition.8 Such patients should undergo immediate endo-
scopic evaluation of the sinuses and any excised mucosa or bone
stained using silver-impregnated stains. Surgical debridement of
all necrotic tissue and initiation of high-dose amphotericin B are
mandatory.8 Immunosuppressive agents should be discontinued, if
possible.
The most common organisms of the non-invasive forms, as in
our patient with a history of AFS, are the dematiaceous molds
(Bipolaris, Curvularia and Pseudallescheria) and the hyaline molds
(Aspergillus and Fusarium).7,8 The overall incidence of AFS is
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rhinosinusitis requiring surgery, Schubert estimated the incidence
to be from 6% to 9%.9 Usually, AFS presents in immunocompetent
patients. A suspicion of AFS should arise in patients with atopy,
chronic sinusitis, nasal polyps, and intractable symptoms, despite
adequate treatment for bacterial sinusitis. In one case series, 100%
of patients had a history of polyps, 54% had asthma, 27% had aspirin
sensitivity, 65% had eosinophilia, and 69% had increased total IgE
levels.10
The diagnostic criteria for AFS consist of: (1) the presence of
‘allergic mucin’ (laminated accumulations of intact and degen-
erating eosinophils, Charcot–Leyden crystals, cellular debris, and
sparse hyphae rarely visualized without fungal stains), (2)
demonstration of fungal hyphae in the allergic mucin, (3)
radiologically conﬁrmed sinusitis, and (4) no evidence of fungal
invasion of submucosa, blood vessels, or bone.8
In AFS, the adjacent sinus mucosa has a mixed cellular
inﬁltrate of eosinophils, plasma cells, and lymphocytes. Buzina
et al. questioned whether an inappropriate response of
eosinophilic granulocytes to the mold rather than allergy (IgE
mediated) may be the mechanism of the chronic inﬂammation.5
However, others believe that type I and III hypersensitivity
reactions underlie the pathogenesis of this disease.4 Further-
more the allergic mucin and polyps may form a partially
calciﬁed expansile mass that obstructs sinus drainage and
perpetuates the bacterial sinusitis often associated with AFS.
Growth of the mass may lead to pressure-induced erosions of
the bone, rupture of sinus walls, and occasional sinus leakage
into the orbits and brain.8 Therefore, as in our patient, suspicion
of invasive disease should arise if the patient presents with
fevers, worsening sinus pain, or headaches.
There are no universally accepted treatment protocols for AFS,
however AFS requires frequent sinus irrigationwithwarm isotonic
saline to prevent impaction of mucus, and recurrent endoscopic
nasal polyp resection. Postoperative changes in total serum IgE
mirror the clinical status and should be followed as they can
predict disease recurrence.7,11 Additionally, postoperative oral and
intranasal corticosteroids should be administered. Oral corticoste-
roid reduces disease activity and forestalls the need for recurrent
sinus surgery.7 Furthermore, aggressive allergy management
including allergen immunotherapy may be useful. However
despite aggressive surgical debridement, sinus aeration, and
medical management, which clearly improves patient symptoms,
AFS recurrence rates remain high.12
In the past years, AFS has been found to be analogous in several
ways to allergic bronchopulmonary aspergillosis (ABPA). Both are
chronic inﬂammatory respiratory tract disorders that are driven by
hypersensitivity responses to the presence of small numbers of
extramucosal fungi found growing within airway-impacting
allergic mucin. Medical treatment of AFS has been modeled to
an extent after treatment approaches for ABPA, which includes the
use of postoperative oral corticosteroids and aggressive antialler-
gic inﬂammation therapy.9 Stevens et al., in a multicenter
randomized control trial, found that high-dose itraconazole
therapy was effective in managing ABPA without added toxicity.13
The underlying mechanism of systemic itraconazole therapy is
thought to be a decreased pulmonary antigenic fungal load,thereby decreasing immunologic responses. Therefore, due to the
pathological, clinical, and therapeutic similarity of AFS to ABPA,
itraconazole has been increasingly used for AFS. Chan et al.
performed an uncontrolled pilot study utilizing itraconazole for>3
months in 32 patients with AFS who were refractory to
conventional therapy; 37% had endoscopic improvement.14
Additionally, Rains and Mineck reviewed the use of their high-
dose itraconazole protocol, with short-burst low-dose oral
corticosteroids, topical corticosteroids, and endoscopic surgery,
and also concluded that it is a safe and clinically effective regimen
in the management of AFS.15 Therefore, itraconazole should be
considered as a reasonable adjunct in the management of AFS.
In summary, AFS should be strongly suspected in patients who
present with recurrent episodes of sinusitis requiring multiple
polyp resections, and failed medical responses. In order to achieve
the best clinical outcome and decrease disease recurrence and
progression, patients should undergo early endoscopic sinus
surgery and aggressive medical management, including frequent
sinus irrigation with warm isotonic saline, steroids, immunother-
apy where necessary, and prolonged itraconazole therapy in
refractory cases. Close follow-up and coordination of treatment by
both medical and surgical physicians as a team leads to the best
clinical outcomes.11 Even though AFS is historically considered
non-invasive, there have been reports of invasion into parasinus
structures. Furthermore, there are no studies evaluating the early
red ﬂags and risk factors to suspect when AFS may progress
towards an invasive form. Consequently, a high clinical suspicion is
warranted.
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